Trial site
Associated Medical Professionals of NY
Syracuse, New York 13210, United StatesNot linked to an institution yet
- 9running trials
- 1closed trial
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 34 trials
- Phase 1/23 trials
- Phase 23 trials
- Status
- Active, not recruiting6 trials
- Recruiting3 trials
- Completed1 trial
- Lead sponsor
- Janssen Research & Development, LLC2 trials
- Brigham and Women's Hospital1 trial
- CG Oncology, Inc.1 trial
- Dendreon1 trial
- enGene, Inc.1 trial
- and 4 more
Running trials
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06995677· Phase 2· Tyra Biosciences, Inc· Source
Contact: Gina Risdall
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· Phase 3· CG Oncology, Inc.· Source
Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT06134232· Phase 2· Dendreon· Source
Contact: Christopher Pieczonka, MD
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722· Phase 1/2· enGene, Inc.· Source
Contact: enGene clinical trials
Active, not recruiting
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
INTREPId (INTermediate Risk Erection PreservatIon Trial)
NCT04025372· Phase 2· Brigham and Women's Hospital· Source
Active, not recruiting
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
NCT02138734· Phase 1/2· ImmunityBio, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error